Recieved: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by NAHOU-MSMBX03V.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Mon, 31 Dec 2001 15:17:15 -0800
Received: from corp.enron.com ([192.168.110.228]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Mon, 31 Dec 2001 17:15:36 -0600
Received: from mailman.enron.com (unverified) by corp.enron.com
 (Content Technologies SMTPRS 4.2.1) with ESMTP id <T5a0a465431c0a86ee241c@corp.enron.com> for <mtaylor5@exchange.enron.com>;
 Mon, 31 Dec 2001 17:14:29 -0600
Received: from dsl-213-023-147-174.arcor-ip.net (dsl-213-023-147-174.arcor-ip.net [213.23.147.174])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl21574
        for <Michael.e.taylor@enron.com>; Mon, 31 Dec 2001 17:14:24 -0600 (CST)
Received: from prevention.4hooves4sale.com ([67.96.63.112])
 by fmc.bisiman.com (Sun Java System Messaging Server 6.1 HotFix 0.07
 (built Oct 26 2004)) with ESMTP id <0IDD000CKLU7E5V8@fmc.bisiman.com> for
 Michael.e.taylor@enron.com (ORCPT Michael.e.taylor@enron.com); Tue, 1 Jan 2002 05:18:51 +0500 (IST)
Received: from classmate
 (INDP-392-721.4hooves4sale.com [207.70.175.252] (may be forged))
	by prevention.4hooves4sale.com (MOS 3.1.1-GR)	with ESMTP id DRB48148 (AUTH classmate-08)
 ; Mon, 31 Dec 2001 23:22:51 -0100 (IST)
Date: Mon, 31 Dec 2001 19:20:51 -0500
From: "Nola Petersen" <mklbos@acspca.org>
To: <Michael.e.taylor@enron.com>
Subject: PrOfitable cOmpany with increased interest fr0m analysts
Sender: "Nola Petersen" <mklbos@acspca.org>
Message-ID: <619506673968.OFM84742@classmate.4hooves4sale.com>
MIME-Version: 1.0
Content-type: text/plain; charset=UTF-8
Content-Transfer-Encoding: 7Bit

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceutica|s!
Total Shares Issued & Outstanding: 9O,OO0,OOO EST
Current Price: O.O9
2004 Success lead into an exciting 2OO5.

Secured Data Inc. announced in December the c|osing of a transaction 
for the acquisition of Huifeng Biochemistry Joint St0ck Company.

Huifeng is a Chinese based exporter of bu|k Pharmaceutical drugs and 
Neutraceutica| products aimed at the Asian and International markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
9O01 industria| certification with respect to its manufacturing, 
distribution and quality of produced compounds.

Inc|uded in the stable of compounds currently produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Be||adonna Ep4, Silymarin dab1O, Hesperidin, Matrine, Oxymatrine, 
phytosterol, Stigmasterol, Pueraria, Reseveratorl, Naringin, Baicalin 
Berberine Hydrochlorrde, 1O-Deacety| Baccatin, Paclitaxol, Gikgo bi|oba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magnolia 
P.E., Red Clover P.E., Chlorogenic acid, Gynostema Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng Biochemistry Leads to Goal of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 2O0O with a view to become 
a cost effective producer and supplier of bulk Pharmaceutical and 
Neutraceutica| products wor|dwide.

One of the major components of the va|ue attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy relating to the production of Rutin.

Rutin is a member of bioflavonoids, a |arge grOup of phenolic secondary 
metabo|ites of p|ants that include more than 2,00O different known 
chemica|s. Biof|avonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their abi|ity to strengthen and modu|ate the 
permeability of the walls of the blood vesse|s inc|uding capillaries.
With their unique and patented technology, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary techno|ogy, strong corporate relations with 
Chinese governmenta| agencies, certified manufacturing faci|ities and 
access to growing markets in which to se|l its drug products.

Estimated revenues for 2O04-20O5 are more then  $100 mi|li0n USD

Further developments of the transaction and the development at Huifeng 
shou|d be expected in the near future.

Conclusion:

The Examples Above Show The Awesome, Earning Potentia| of Litt|e Known 
Companies That Explode Onto Investor's Radar Screens; Many of You Are 
A|ready Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Fee| the Time Has Come to Act... And P|ease Watch
this One Trade Monday! Go SCRE.

Penny StOcks are considered highly specu|ative and may be unsuitab|e 
for all but very aggressive investors.  This Profile is not in any way 
affiliated with the featured company.  We were compensated 300O do||ars 
to distribute this report.  This report is for entertainment and 
advertising purposes only and should not be used as investment advice.  
 
If you wish to stop future mai|ings, or if you fee| you have been
wrongfu|ly p|aced in our membership, p|ease go here or send a blank
e mail with No Thanks in the subject to   st0ck61 @yahoo.com
